OPTIMMAL
An Open-Label, Non-Randomized, Multicenter, Phase II Study to Study the Efficacy of Talquetamab (JNJ-64407564) and Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma (OPTIMMAL)
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 2
- Enrollment
- 30 patients (estimated)
- Sponsors
- Stanford University Cancer Institute (Palo Alto)
- Collaborators
- Janssen Pharmaceuticals
- Tags
- Bispecific Antibody, GPRC5D, Maintenance
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1920
- NCT Identifier
- NCT06461988
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.